BIOREGENX, INC. — Earnings

Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR

Next earnings (estimated): Wed, April 1, 2026 30 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)

Recent earnings · last 8 quarters

Quarter endRevenueYoYNet IncomeYoYOp. Margin
2025-12-31$386K↓-16.3%
2025-09-30$508K↓-14.8%$-81K↑+79.6%-1.7%
2025-06-30$446K↓-39.2%$-178K↑+83.9%-24.1%
2025-03-31$515K↓-6.3%$-267K↑+91.5%-37.4%
2024-12-31$460K↓-32.1%
2024-09-30$596K↓-25.0%$-395K↑+84.3%-54.9%
2024-06-30$734K↓-15.0%$-1M↓-86.1%-141.7%
2024-03-31$550K↓-48.9%$-3M↓-1271.6%-560.4%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2025 (Q4)

Revenue
$386K
↓-16.3% -$75K YoY

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.

Margin trends · 16 quarters

margin trajectory tells the operating-leverage story
Gross Margin↑+12.6pts
82.7%
Operating Margin↑+53.2pts
-1.7%
Net Margin↑+50.4pts
-15.9%

Go deeper